A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

被引：0
|
作者：
Fuchs, C. [1 ]
Shahidi, J. [2 ]
Mathew, L. [2 ]
Qin, A. [2 ]
Van Cutsem, E. [3 ,4 ]
机构：
[1] Yale Canc Ctr, Smilow Canc Hosp, New Haven, CT USA
[2] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[3] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium
[4] Katholieke Univ Leuven, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.266
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-184
引用
收藏
页码：S150 / S150
页数：1
相关论文
共 50 条
  • [41] Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Positive Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Progressed On or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04, DG-04): A Randomized Phase 3 Study
    Shitara, Kohei
    Barlaskar, Ferdous
    Franke, Fabio A.
    Kawaguchi, Yoshinori
    Shen, Lin
    Kamio, Takahiro
    Meinhardt, Gerold
    Tabernero, Josep
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 95 - 95
  • [42] Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer
    Modi, Shanu
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara A.
    Cortes, Javier
    Lee, Caleb
    Liu, Yali
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Baselga, Jose
    Krop, Ian E.
    CANCER RESEARCH, 2021, 81 (04)
  • [43] Impact of HER2 Expression on trastuzumab deruxtecan(T-DXd) efficacy
    Chen, Wanyi
    Drago, Joshua
    Gupta, Avantika
    Liu, Bo
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2024, 84 (06)
  • [44] Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)
    Siena, S.
    Raghav, K.
    Masuishi, T.
    Yamaguchi, K.
    Nishina, T.
    Elez, E.
    Rodriguez, J.
    Chau, I.
    Di Bartolomeo, M.
    Kawakami, H.
    Suto, F.
    Kobayashi, K.
    Koga, M.
    Inaki, K.
    Kuwahara, Y.
    Takehara, I.
    Grothey, A.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S532 - S532
  • [45] Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/ metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
    Shen, L.
    Chen, P.
    Lu, J.
    Wan, Y.
    Zheng, Y.
    Ye, F.
    Yang, J.
    Liu, Y.
    Pan, H.
    Chen, H.
    Sun, M.
    Fan, Q.
    Yuan, Y.
    Chen, K.
    Sun, Z.
    Tian, H.
    Ye, X.
    Peng, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S1542 - S1543
  • [46] PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
    Lu, Z.
    Hennig, S.
    Li, L.
    Kamiyama, E.
    Vaddady, P.
    Abutarif, M.
    Garimella, T.
    Khatri, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S93 - S94
  • [47] Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer
    Chang, Dwan-Ying
    Lin, Chia-Chi
    Chen, Tom Wei-Wu
    Lin, Ching-Hung
    Lee, Jih-Hsiang
    Chao, Ta-Chung
    Liu, Chun-Yu
    Achiwa, Issei
    Kamiyama, Emi
    Okuda, Yasuyuki
    Lee, Caleb
    Chao, Yee
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [48] The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Wei, T.
    Wang, D.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 948 - 949
  • [49] [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 trial (DESTINY-Breast02)
    Andre, Fabrice
    Shahidi, Javad
    Lee, Caleb
    Wang, Kongming
    Krop, Ian E.
    CANCER RESEARCH, 2020, 80 (04)
  • [50] Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
    Siena, Salvatore
    Di Bartolomeo, Maria
    Raghav, Kanwal
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Fakih, Marwan
    Elez, Elena
    Rodriguez, Javier
    Ciardiello, Fortunato
    Komatsu, Yoshito
    Esaki, Taito
    Chung, Ki
    Wainberg, Zev
    Sartore-Bianchi, Andrea
    Saxena, Kapil
    Yamamoto, Eriko
    Bako, Emarjola
    Okuda, Yasuyuki
    Shahidi, Javad
    Grothey, Axel
    Yoshino, Takayuki
    LANCET ONCOLOGY, 2021, 22 (06): : 779 - 789
12345